XIMINO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XIMINO (XIMINO).
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
| Metabolism | Hepatic metabolism is minimal; primarily excreted unchanged in urine and feces. Not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4. |
| Half-life | Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (range 0.6-1.0 L/kg), indicating extensive tissue distribution and penetration into extravascular spaces. |
| Bioavailability | Oral: 60% (range 50-70%) due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes to peak plasma concentration; therapeutic effect onset: 1-2 hours. Intravenous: within 5-10 minutes. |
| Duration of Action | 12-24 hours depending on dose and renal function; clinical effect persists for 24 hours after single dose. |
400 mg orally twice daily with food for 7 days.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl ≥30 mL/min: No adjustment. CrCl 15-29 mL/min: 200 mg orally twice daily. CrCl <15 mL/min or hemodialysis: 200 mg orally once daily. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; maximum dose 200 mg twice daily. Child-Pugh C: Not recommended. |
| Pediatric use | ≥12 years (≥45 kg): 400 mg orally twice daily with food for 7 days. <12 years: Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider age-related decline in CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XIMINO (XIMINO).
| Breastfeeding | Excretion into human milk is unknown. Animal studies show high levels in milk. Due to potential for immune suppression and growth retardation, breastfeeding is not recommended during treatment and for 6 weeks after last dose. |
| Teratogenic Risk | XIMINO (xenomycophenolic acid) is contraindicated in pregnancy. First trimester exposure is associated with craniofacial malformations (cleft lip/palate), microtia, and cardiovascular defects in up to 45% of cases. Second and third trimester exposure may lead to intrauterine growth restriction, oligohydramnios, and preterm birth. Use adequate contraception before, during, and 6 weeks after therapy. |
■ FDA Black Box Warning
Not approved for use in patients with severe hepatic impairment; hepatotoxicity has been reported. Fatalities have occurred with hepatic injury. Discontinue if liver injury occurs.
| Serious Effects |
["Hypersensitivity to tetracyclines","Severe hepatic impairment","Concomitant use with isotretinoin (risk of intracranial hypertension)"]
| Precautions | ["Hepatotoxicity: discontinue if signs of liver injury appear.","Photosensitivity: avoid excessive sunlight or UV light.","Use caution in patients with renal impairment; dose adjustment may be needed.","May cause dizziness or blurred vision; avoid driving if affected.","Pregnancy category D; avoid use during pregnancy due to risk of fetal harm.","Pseudoaneurysm formation has been reported in patients with Marfan syndrome."] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count (CBC), liver function tests (LFTs), and renal function monthly. During pregnancy, perform targeted fetal ultrasound for craniofacial and cardiac anomalies at 18-22 weeks. Measure amniotic fluid index if oligohydramnios suspected. Monitor neonatal CBC and infection signs for 2 weeks postpartum. |
| Fertility Effects | Based on animal studies, XIMINO may impair female fertility by disrupting ovarian cycle and embryo implantation. Male fertility may be reduced due to effects on spermatogenesis. Reversibility of these effects after cessation is unknown. |